Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Crystal structure of Plasmodium falciparum thioredoxin reductase, a validated drug target.

Abstract : Plasmodium falciparum is the vector of the most prevalent and deadly form of malaria, and, among the Plasmodium species, it is the one with the highest rate of drug resistance. At the basis of a rational drug design project there is the selection and characterization of suitable target(s). Thioredoxin reductase, the first protection against reactive oxygen species in the erythrocytic phase of the parasite, is essential for its survival. Hence it represents a good target for the design of new anti-malarial active compounds. In this paper we present the first crystal structure of recombinant P. falciparum thioredoxin reductase (PfTrxR) at 2.9Å and discuss its differences with respect to the human orthologue. The most important one resides in the dimer interface, which offers a good binding site for selective non competitive inhibitors. The striking conservation of this feature among the Plasmodium parasites, but not among other Apicomplexa parasites neither in mammals, boosts its exploitability.
Complete list of metadata

Cited literature [25 references]  Display  Hide  Download
Contributor : Istituto Pasteur Fondazione Cenci Bolognetti Connect in order to contact the contributor
Submitted on : Wednesday, February 26, 2014 - 10:24:02 AM
Last modification on : Thursday, January 6, 2022 - 5:30:02 PM
Long-term archiving on: : Sunday, April 9, 2017 - 6:17:02 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Giovanna Boumis, Giorgio Giardina, Francesco Angelucci, Andrea Bellelli, Maurizio Brunori, et al.. Crystal structure of Plasmodium falciparum thioredoxin reductase, a validated drug target.. Biochemical and Biophysical Research Communications, Elsevier, 2012, 425 (4), pp.806-11. ⟨10.1016/j.bbrc.2012.07.156⟩. ⟨pasteur-00952042⟩



Record views